Brief: Coya Therapeutics Inc - Re-Submits Ind Application To FDA Related To Phase 2 Study Of Coya 302 For Als Treatment - SEC Filing
01/07/2025 13:24
Coya Therapeutics Inc COYA.O: COYA THERAPEUTICS INC - RE-SUBMITS IND APPLICATION TO FDA RELATED TO PHASE 2 STUDY OF COYA 302 FOR ALS TREATMENT - SEC FILING COYA THERAPEUTICS INC - TO INITIATE PHASE 2 STUDY UPON IND ACCEPTANCE - SEC FILING Source text: [ID:n0001193125-25-153465] Further company coverage: COYA.O
Recent news on Coya Therapeutics
See all newsCoya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Coya Therapeutics Q2 net loss widens as R&D costs rise
Coya Therapeutics Inc expected to post a loss of 34 cents a share - Earnings Preview
Brief: Coya Therapeutics Entered Into Sales Agreement, May Offer And Sell From Time To Time Shares Of Co's Common Stock For Up To $30 Million
Brief: Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation For Coya 302 For The Treatment Of Amyotrophic Lateral Sclerosis (ALS)